Healthwell Acquisition Corp. I (HWEL) to Combine with Starton Therapeutics in $339M Deal

Healthwell Acquisition Corp. I (NASDAQ:HWEL) has entered into a definitive agreement to combine with clinical-stage biotech firm Starton at an enterprise value of $339 million. Paramus, New Jersey-based Starton is developing a line of treatments to improve efficacies in delivering drugs for certain types of cancer and mitigating the side effects of chemotherapy. The combined
Read More